DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

PAYX

154.48

+0.25%↑

CPRT

57.2

+1.13%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

PAYX

154.48

+0.25%↑

CPRT

57.2

+1.13%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

PAYX

154.48

+0.25%↑

CPRT

57.2

+1.13%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

PAYX

154.48

+0.25%↑

CPRT

57.2

+1.13%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

PAYX

154.48

+0.25%↑

CPRT

57.2

+1.13%↑

HEICA

212.51

+0.9%↑

Search

Ocugen Inc

Uždarymo kaina

0.64 -8.57

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.62

Max

0.71

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-910K

-14M

Pardavimai

-372K

764K

Pelnas, tenkantis vienai akcijai

-0.05

Pelno marža

-1,816.754

Darbuotojai

95

EBITDA

-603K

-13M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+839.44% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

57M

233M

Ankstesnė atidarymo kaina

9.21

Ankstesnė uždarymo kaina

0.64

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

Ocugen Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-04-08 14:32; UTC

Pagrindinės rinkos jėgos

Ocugen Gets FDA Clearance for IND Amendment for OCU400

Akcijų palyginimas

Kainos pokytis

Ocugen Inc Prognozė

Kainos tikslas

By TipRanks

839.44% į viršų

12 mėnesių prognozė

Vidutinis 6.67 USD  839.44%

Aukščiausias 8 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ocugen Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.5163 / 0.7995Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.